I-MAB SPONS.ADS/1 -0001 (0VY) - Net Assets
Based on the latest financial reports, I-MAB SPONS.ADS/1 -0001 (0VY) has net assets worth €230.94 Million EUR (≈ $269.99 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€260.52 Million ≈ $304.58 Million USD) and total liabilities (€29.58 Million ≈ $34.58 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check I-MAB SPONS.ADS/1 -0001 (0VY) strategic asset index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €230.94 Million |
| % of Total Assets | 88.65% |
| Annual Growth Rate | -24.62% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 23.24 |
I-MAB SPONS.ADS/1 -0001 - Net Assets Trend (2021–2025)
This chart illustrates how I-MAB SPONS.ADS/1 -0001's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see I-MAB SPONS.ADS/1 -0001 (0VY) market capitalisation.
Annual Net Assets for I-MAB SPONS.ADS/1 -0001 (2021–2025)
The table below shows the annual net assets of I-MAB SPONS.ADS/1 -0001 from 2021 to 2025. Also explore 0VY net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €230.94 Million ≈ $269.99 Million |
+14.80% |
| 2024-12-31 | €201.16 Million ≈ $235.18 Million |
-17.08% |
| 2023-12-31 | €242.58 Million ≈ $283.61 Million |
-42.48% |
| 2022-12-31 | €421.77 Million ≈ $493.09 Million |
-41.04% |
| 2021-12-31 | €715.33 Million ≈ $836.29 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to I-MAB SPONS.ADS/1 -0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 64910048835.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.56 Billion | 676.90% |
| Total Equity | €230.94 Million | 100.00% |
I-MAB SPONS.ADS/1 -0001 Competitors by Market Cap
The table below lists competitors of I-MAB SPONS.ADS/1 -0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CB Financial Services Inc
NASDAQ:CBFV
|
$189.44 Million |
|
Electreon Wireless Ltd
TA:ELWS
|
$189.50 Million |
|
Guangdong Electric Power Devel
SHE:200539
|
$189.57 Million |
|
Ames National Corporation
NASDAQ:ATLO
|
$189.58 Million |
|
HARIM Co. Ltd
KQ:136480
|
$189.26 Million |
|
Lindsay Australia Ltd
AU:LAU
|
$189.18 Million |
|
Tatung System Technologies
TWO:8099
|
$189.17 Million |
|
Inversora Juramento SA
BA:INVJ
|
$189.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in I-MAB SPONS.ADS/1 -0001's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 201,160,000 to 230,941,000, a change of 29,781,000 (14.8%).
- Net loss of 46,269,000 reduced equity.
- New share issuances of 61,714,000 increased equity.
- Other factors increased equity by 14,336,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-46.27 Million | -20.03% |
| Share Issuances | €61.71 Million | +26.72% |
| Other Changes | €14.34 Million | +6.21% |
| Total Change | €- | 14.80% |
Book Value vs Market Value Analysis
This analysis compares I-MAB SPONS.ADS/1 -0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.61x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.36x to 1.61x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €3.89 | €1.40 | x |
| 2022-12-31 | €2.21 | €1.40 | x |
| 2023-12-31 | €1.31 | €1.40 | x |
| 2024-12-31 | €1.07 | €1.40 | x |
| 2025-12-31 | €0.87 | €1.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently I-MAB SPONS.ADS/1 -0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -20.03%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.13x
- Recent ROE (-20.03%) is above the historical average (-51.17%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -51.14% | -2648.70% | 0.02x | 1.23x | €-437.32 Million |
| 2022 | -87.98% | 0.00% | 0.00x | 1.40x | €-413.23 Million |
| 2023 | -85.63% | -32868.51% | 0.00x | 1.52x | €-231.99 Million |
| 2024 | -11.05% | 0.00% | 0.00x | 1.06x | €-42.35 Million |
| 2025 | -20.03% | 0.00% | 0.00x | 1.13x | €-69.36 Million |
Industry Comparison
This section compares I-MAB SPONS.ADS/1 -0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $756,820,930
- Average return on equity (ROE) among peers: -121.80%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| I-MAB SPONS.ADS/1 -0001 (0VY) | €230.94 Million | -51.14% | 0.13x | $189.29 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $113.23 Million | -53.64% | 0.85x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $3.94 Million | -301.40% | 1.87x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $115.18 Million | -247.79% | 2.83x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-6.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $5.50 Billion | 15.15% | 0.13x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $39.63 Million | -145.12% | 5.94x | $825.52 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $-2.33 Million | 0.00% | 0.00x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $1.05 Billion | -42.40% | 0.17x | $1.82 Billion |
About I-MAB SPONS.ADS/1 -0001
NovaBridge Biosciences, a biotechnology company, focuses on the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. It is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; VIS-101, a bispecific antibody, which … Read more